Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Effectiveness of droxidopa compared to midodrine in standing blood pressure and orthostatic tolerance in adults with neurogenic orthostatic hypotension: a systematic review protocol.

Patrick K, Martin T.

JBI Database System Rev Implement Rep. 2017 Sep;15(9):2287-2294. doi: 10.11124/JBISRIR-2016-003306.

PMID:
28902695
2.

Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease.

Kremens D, Lew M, Claassen D, Goodman BP.

Clin Auton Res. 2017 Jul;27(Suppl 1):29-31. doi: 10.1007/s10286-017-0434-6. Epub 2017 Jul 3. No abstract available.

3.

Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.

Goodman BP, Claassen D, Mehdirad A.

Clin Auton Res. 2017 Jul;27(Suppl 1):17-19. doi: 10.1007/s10286-017-0431-9. Epub 2017 Jun 19. No abstract available.

PMID:
28631223
4.

Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy.

Goodman BP, Gupta F.

Clin Auton Res. 2017 Jul;27(Suppl 1):21-23. doi: 10.1007/s10286-017-0432-8. Epub 2017 Jun 19. No abstract available.

5.

Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus.

Vernino S, Claassen D.

Clin Auton Res. 2017 Jul;27(Suppl 1):33-34. doi: 10.1007/s10286-017-0435-5. Epub 2017 Jul 3. No abstract available.

6.

New developments in the management of neurogenic orthostatic hypotension.

Biaggioni I.

Curr Cardiol Rep. 2014 Nov;16(11):542. doi: 10.1007/s11886-014-0542-z. Review.

PMID:
25303896
7.

Droxidopa (Northera) for neurogenic orthostatic hypotension.

[No authors listed]

Med Lett Drugs Ther. 2015 Jun 22;57(1471):92-3. No abstract available.

PMID:
26079764
8.

Chemical pharmacotherapy for the treatment of orthostatic hypotension.

Cheshire WP.

Expert Opin Pharmacother. 2019 Feb;20(2):187-199. doi: 10.1080/14656566.2018.1543404. Epub 2018 Nov 8. Review.

PMID:
30376728
9.

Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.

Isaacson SH, Skettini J.

Vasc Health Risk Manag. 2014 Apr 3;10:169-76. doi: 10.2147/VHRM.S53983. eCollection 2014. Review.

10.

Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension.

Gupta F, Karabin B, Mehdirad A.

Clin Auton Res. 2017 Jul;27(Suppl 1):15-16. doi: 10.1007/s10286-017-0430-x. Epub 2017 Jul 11. No abstract available. Erratum in: Clin Auton Res. 2017 Sep 9;:.

11.

Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?

Kaufmann H.

Clin Auton Res. 2017 Jul;27(Suppl 1):1-3. doi: 10.1007/s10286-017-0426-6. Epub 2017 Jun 16. No abstract available.

PMID:
28623419
12.

Differential diagnosis of suspected neurogenic orthostatic hypotension in a patient with Parkinson disease.

Lew M, Kremens D.

Clin Auton Res. 2017 Jul;27(Suppl 1):5-7. doi: 10.1007/s10286-017-0427-5. Epub 2017 Jul 3. No abstract available.

13.

Midodrine efficacy in orthostatic hypotension.

Singer W, Joyner MJ, Sandroni P, Benarroch EE, Fealey RD, Mandrekar J, Low PA.

J Gen Intern Med. 2014 Nov;29(11):1440-1. doi: 10.1007/s11606-014-3014-7. No abstract available.

14.

Midodrine efficacy in orthostatic hypotension.

Murad MH, Singh B, Parsaik AA.

J Gen Intern Med. 2014 Nov;29(11):1442-3. doi: 10.1007/s11606-014-3013-8. No abstract available.

15.

Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.

Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA.

JAMA. 1997 Apr 2;277(13):1046-51. Erratum in: JAMA 1997 Aug 6;278(5):388.

PMID:
9091692
16.

Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.

Claassen D, Lew M.

Clin Auton Res. 2017 Jul;27(Suppl 1):13-14. doi: 10.1007/s10286-017-0429-3. Epub 2017 Jun 19. No abstract available.

17.

Orthostatic hypotension for the cardiologist.

Mar PL, Raj SR.

Curr Opin Cardiol. 2018 Jan;33(1):66-72. doi: 10.1097/HCO.0000000000000467. Review.

18.

Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension.

Vernino S, Lew M, Kremens D.

Clin Auton Res. 2017 Jul;27(Suppl 1):35-37. doi: 10.1007/s10286-017-0436-4. Epub 2017 Jun 16. No abstract available.

19.

L-DOPS therapy for refractory orthostatic hypotension in autoimmune autonomic neuropathy.

Gibbons CH, Vernino SA, Kaufmann H, Freeman R.

Neurology. 2005 Oct 11;65(7):1104-6.

PMID:
16217067
20.

Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials.

Parsaik AK, Singh B, Altayar O, Mascarenhas SS, Singh SK, Erwin PJ, Murad MH.

J Gen Intern Med. 2013 Nov;28(11):1496-503. doi: 10.1007/s11606-013-2520-3. Epub 2013 Jun 18. Review.

Supplemental Content

Support Center